Teprotumumab

Drug Overview

In the specialized field of Endocrinology, Thyroid Eye Disease (TED) has historically been one of the most challenging conditions to manage. For decades, patients faced a “watchful waiting” approach or high-dose steroids with limited success. Teprotumumab represents a paradigm shift in therapy, acting as the first medication designed to target the underlying biological cause of the disease rather than merely masking the symptoms.

This medication belongs to the IGF-1 Receptor Antagonist drug class. It is a highly specialized Biologic therapy that provides a non-surgical alternative to reduce eye bulging, double vision, and orbital pain.

Generic Name / Active Ingredient: Teprotumumab-trbw
US Brand Name: Tepezza
Drug Class: Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist
Route of Administration: Intravenous (IV) Infusion
FDA Approval Status: FDA-approved in 2020; it is indicated for the treatment of Thyroid Eye Disease regardless of disease activity or duration.

What Is It and How Does It Work? (Mechanism of Action)

Teprotumumab is a fully human monoclonal antibody that functions as a highly precise Targeted Therapy. To understand its action, one must look at the cellular environment behind the eyes of a patient with Thyroid Eye Disease.

Molecular and Hormonal Pathway

In TED, the body’s immune system mistakenly attacks the soft tissues, fat, and muscles behind the eyes. This attack is driven by a complex interaction between the Thyroid Stimulating Hormone Receptor (TSHR) and the Insulin-like Growth Factor-1 Receptor (IGF-1R). These two receptors form a “complex” on the surface of fibrocytes (specialized connective tissue cells).

Competitive Antagonism: Teprotumumab binds with high affinity specifically to the IGF-1 Receptor.
Signal Blockade: By attaching to IGF-1R, the drug physically blocks the receptors from being activated by the body’s natural IGF-1 or by the autoantibodies found in Graves’ disease.
Reducing Inflammation: When these receptors are blocked, the cells stop producing inflammatory chemicals (cytokines) and hyaluronic acid.
Tissue Remodeling: Crucially, this prevents the accumulation of excess fluid and the growth of new fat and muscle tissue behind the eye (adipogenesis and fibrosis).

By deactivating this signaling pathway, the drug leads to a reduction in muscle and fat volume, allowing the eyes to move back into their natural position (reducing proptosis) and relieving pressure on the optic nerve.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved use for Teprotumumab is the treatment of Thyroid Eye Disease (TED). It is indicated for patients in both the “active” phase (characterized by redness, swelling, and pain) and the “chronic” phase (where inflammation has subsided but bulging and double vision remain).

Other Approved & Off-Label Uses

Graves’ Ophthalmopathy: This is the clinical term for TED in the context of Graves’ disease.
Compressive Optic Neuropathy: While clinical trials are ongoing for specific emergency protocols, it is often utilized in this category to prevent permanent blindness in patients whose eye muscles are so swollen they are compressing the optic nerve.

Primary Endocrinology Indications:

Proptosis Reduction: Actively reducing “bulging” of the eyes.
Diplopia Improvement: Restoring hormonal and cellular balance to the eye muscles to reduce double vision.
Orbital Decompression: Providing a “medical decompression” to eliminate pain and pressure without invasive surgery.

Dosage and Administration Protocols

Teprotumumab is administered via a series of eight intravenous infusions given every three weeks. The dose is calculated based on the patient’s body weight.

Indication	Standard Dose (Infusion 1)	Maintenance Dose (Infusions 2–8)	Frequency
Thyroid Eye Disease	10 mg/kg	20 mg/kg	Every 3 weeks

Administration Details

Duration: The first two infusions are typically administered over 90 minutes. If well-tolerated, subsequent infusions may be shortened to 60 minutes.
Cycle: A full course of treatment consists of 8 total infusions (approximately 5 months of therapy).
Location: Infusions must be performed in a hospital, clinic, or specialized infusion center under the supervision of a healthcare professional.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical research conducted between 2020 and 2026 has established Teprotumumab as the most efficacious non-surgical treatment for TED.

Proptosis (Bulging) Reduction: In pivotal trials (OPTIC and OPTIC-X), 83% of patients achieved a clinically significant reduction in eye bulging (mean reduction of 3.3 mm) compared to only 10% in the placebo group.
Diplopia (Double Vision) Improvement: Over 68% of patients saw a significant improvement in double vision, with many experiencing a complete resolution of symptoms.
Clinical Activity Score (CAS): Patients showed a mean reduction in the CAS (a measure of pain, redness, and swelling) of nearly 4 points, indicating a rapid “cooling” of the disease.
Long-term Efficacy: 2024–2025 follow-up studies confirm that for the majority of patients, the results are durable, with only a small percentage requiring a second course of therapy years later.

Safety Profile and Side Effects

NO BLACK BOX WARNING

While Teprotumumab does not have a Black Box Warning, it has specific side effects related to its interaction with the IGF-1 pathway that require careful monitoring.

Common Side Effects (>10%)

Muscle Spasms: Frequently reported cramps, particularly in the legs.
Nausea and Diarrhea: Generally mild gastrointestinal upset.
Alopecia (Hair Thinning): Temporary thinning of hair, which is typically reversible after treatment ends.
Fatigue: Feeling tired for a few days following the infusion.
Menstrual Disorders: Changes in cycle or flow in female patients.

Serious Adverse Events

Hearing Changes: Tinnitus (ringing in the ears), muffled hearing, or permanent hearing loss. Baseline and periodic hearing tests are mandatory.
Hyperglycemia: Since IGF-1R is structurally related to the insulin receptor, the drug can cause spikes in blood sugar. This is a critical concern for patients with pre-existing Type 2 Diabetes.
Infusion Reactions: Includes high blood pressure, feeling hot, or a rapid heart rate during the infusion.
IBD Exacerbation: May worsen symptoms in patients with a history of Inflammatory Bowel Disease.

Management Strategies: Patients with diabetes must monitor blood sugar closely. Hearing should be tested by an audiologist before, during, and after the 8-infusion cycle to detect any changes early.

Research Areas

Direct Clinical Connections

Research from 2024 to 2026 is investigating the drug’s impact on Insulin Sensitivity. Because the IGF-1 receptor and insulin receptor are so similar, researchers are studying how the drug affects the Hypothalamic-Pituitary-Adrenal (HPA) Axis and long-term glucose metabolism. There is also research into the drug’s role in Pancreatic Beta-Cell Preservation in diabetic patients who require this therapy.

Generalization & Advancements

The endocrinology community is exploring Novel Delivery Systems, including subcutaneous (under the skin) injections that would eliminate the need for long IV infusions. Additionally, 2026 research into Biosimilars is underway to make this high-cost Biologic more accessible to patients worldwide.

Severe Disease & Prevention

Long-term studies focus on the drug’s efficacy in preventing Compressive Optic Neuropathy, the most severe complication of TED that can lead to permanent blindness. By treating earlier, physicians hope to prevent the need for emergency orbital surgery.

Patient Management and Clinical Protocols

Pre-treatment Assessment

Baseline Diagnostics: Serum glucose and HbA1c (especially in diabetic patients).
Audiogram: A formal hearing test performed by a licensed audiologist.
Imaging: A baseline CT or MRI of the orbits (eye sockets) to document muscle and fat volume.
Pregnancy: A negative pregnancy test is mandatory, as the drug can cause fetal harm.

Monitoring and Precautions

Vigilance: Monitoring for “therapeutic escape” or recurrence of symptoms after the 8th infusion.
Blood Sugar: Weekly glucose monitoring for patients with diabetes or pre-diabetes.
Hearing: Patients must report any muffled hearing, ringing in the ears, or “fullness” immediately.

“Do’s and Don’ts” List

DO use highly effective birth control during treatment and for 6 months after the final dose.
DO stay hydrated before each infusion to help with IV access.
DO keep your hearing test appointments even if you feel your hearing is fine.
DON’T skip infusions; the 3-week cycle is critical for effective tissue remodeling.
DON’T ignore new or worsening stomach pain or diarrhea if you have a history of IBD.

Legal Disclaimer

This document is for informational purposes only and does not constitute medical advice. Teprotumumab must be managed by an Endocrinologist, Neuro-ophthalmologist, or Orbital Surgeon. Do not start or stop treatment without professional consultation. All data is current as of 2026.